Compare Novo Nordisk A/S (NVO) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Global X Robo Global Robotics & Automation ETF — how do they compare? Novo Nordisk A/S trades at $38.62 (market cap $165.31B), while Global X Robo Global Robotics & Automation ETF trades at $81.23 (market cap $2.06B). The key difference: Novo Nordisk A/S is far larger — about 80.2× Global X Robo Global Robotics & Automation ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Global X Robo Global Robotics & Automation ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Global X Robo Global Robotics & Automation ETF for 36 Days on average.
| NVO | ROBO | |
|---|---|---|
Market Cap | $165.31B | $2.06B |
Volume | 11,432,838 | 148,111 |
Sector | Health | Sector/Thematic |
52-Week High | $63.98 | $90.34 |
52-Week Low | $35.29 | $63.04 |
Typical Hold Time | 116 Days | 36 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
ROBO trades at $81.82, down 1.89% today amid mixed technical signals. The overall technical outlook remains bullish with strong moving average support, though oscillators show bearish momentum with RSI levels above 79 indicating potential overbought conditions. Recent news highlights accelerating robotics adoption across manufacturing, healthcare, and military applications, with Q2 2026 earnings showing broadening demand for physical AI technologies.
The robotics ETF offers diversified exposure to a sector benefiting from labor shortages and AI infrastructure growth. Key risks include valuation concerns amid rapid sector expansion and potential market volatility. Analyst coverage remains positive on long-term robotics adoption trends, though current technical indicators suggest near-term consolidation may be needed after recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
